<DOC>
	<DOCNO>NCT01116531</DOCNO>
	<brief_summary>Tramadol opioid analgesic , widely use treatment acute neuropathic pain . Treatment neuropathic pain often require combination pain medication due complex nature neuropathic pain frequent inadequate response drug treatment . Common drug use concomitantly tramadol SNRI antidepressant duloxetine anticonvulsant pregabalin . Both tramadol duloxetine serotonergic effect duloxetine also potential inhibit metabolism tramadol . The objective study investigate pharmacokinetics pharmacodynamic interaction oral tramadol duloxetine pregabalin patient chronic neuropathic pain due postherpetic neuralgia diabetic polyneuropathy . All subject receive tramadol duloxetine tramadol pregabalin randomize double-blind order . Primary end point O-desmethyltramadol concentration .</brief_summary>
	<brief_title>Efficacy , Safety , Tolerability Pharmacokinetics Concomitant Administration Tramadol With Duloxetine Pregabalin</brief_title>
	<detailed_description />
	<mesh_term>Polyneuropathies</mesh_term>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Neuralgia , Postherpetic</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<mesh_term>Duloxetine Hydrochloride</mesh_term>
	<mesh_term>Tramadol</mesh_term>
	<mesh_term>Pregabalin</mesh_term>
	<criteria>Chronic ( ≥ 6 month ) neuropathic pain due postherpetic neuralgia diabetic polyneuropathy Pain intensity ≥ 4 numerical scale 010 Informed consent Clinically significant abnormality laboratory screen Pregnancy Depression Use strong opioids ( morphine , oxycodone , fentanyl , hydromorphone , methadone ) A previous history intolerance allergy study drug related compound additives Existing history seizure , haematological disorder , clinically significant renal , hepatic , respiratory , cardiac psychiatric disease , dementia , drug allergy Previous present alcoholism , drug abuse , psychological emotional problem cognitive impairment likely invalidate inform consent limit ability subject comply protocol requirement Concomitant drug therapy know cause significant enzyme induction inhibition CYP 1A2 , 2D6 , 3A4 , 2B6 , drug metabolise CYP2D6 enzyme , antidepressant , MAOinhibitors , nonsteroidal antiinflammatory analgesic .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacodynamics</keyword>
	<keyword>Interaction</keyword>
	<keyword>tramadol</keyword>
	<keyword>duloxetine</keyword>
	<keyword>pregabalin</keyword>
</DOC>